The Latest Updates from ReSPECT Clinical Trials

Attending SNO/ASCO CNS Conference in Denver this week? So are we! Read the full details on our upcoming symposium, oral presentations, and posters: https://bit.ly/3LFxFMS...

Plus Therapeutics is proud to be a Bronze Supporter and Exhibitor at the SNO / ASCO CNS Conference this year! Come by our booth, posters, and presentations we have going on throughout the conference. Detail including times and presentation titles:...

You're Invited to our symposium "Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases," presented at the SNO/ASCO CNS conference in Denver. More information & RSVP: https://bit.ly/4bM777e "Emerging Novel Diagnostic and Therapeutic...

UPCOMING PRESENTATIONS: Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference and scheduled to present new data, highlighting progress in its therapeutics and diagnostics programs for Leptomeningeal Metastases Read the full details...

"Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered. To learn more about emerging developments, Digital Journal spoke with Marc Hedrick, MD...

Join us at the Gordon Research Conference: Radionuclide Theranostics for the Management of Cancer, being held July 7-12 in Newry, Maine, as Plus Therapeutics takes the stage. Presentation by Melissa Moore, Ph.D. Press Release: https://bit.ly/PSTV_PR...

We are proud to support @glioblastomaakagbm podcast by @glioblastomaresearch! Listen again to the episode "Power and Precision with Plus Therapeutics": https://spoti.fi/3W4O5Dl In their latest episode, they are joined by Holly Gainsboro, a grief specialist and founder...

Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed...

We are excited to have Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center join us as Vice President of Medical Affairs and Medical Director. Dr. Fuller will help lead the...

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled: "Rhenium...

📣 NEW GLIOBLASTOMA PODCAST EPISODE! Link to listen: https://bit.ly/4dZjfUD Thank you to @glioblastomaakagbm by @glioblastomaresearchorg for hosting our very own Dr. Marc Hedrick, President and CEO of Plus Therapeutics in your latest episode. Dr. Hedrick brings his...

In honor of #BrainTumorAwarenessMonth, we would like to reshare some great educational, support and financial resources for patients and caregivers fighting a brain tumor diagnosis. More information can be found on our website at ReSPECT-Trials.com along with...

#ICYMI: Replay the #Glioblastoma Patient Webinar from last week, hosted by Dr. Al Musella. The presentation included information about the ReSPECT-GBM clinical trial's promising targeted radiotherapeutic working to treat Recurrent Glioblastoma and included a lively...

🌟 Happy National Clinical Trials Day! 🌟 Today, we honor the incredible advancements made possible through clinical trials. These pivotal studies bring hope by paving the way for groundbreaking treatments and cures. At Plus Therapeutics, we are proud to be at the...

Exciting News! Our partner, Head for the Cure Foundation has launched a new patient and caregiver resource, “Join Your Path to Hope!” JPH gives personalized guidance and resources for every step of your brain tumor journey within three different paths: medical,...